Literature DB >> 22170910

Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Jennifer D Campbell1, James S Lewis, M Leticia McElmeel, Letitia C Fulcher, James H Jorgensen.   

Abstract

Extended-spectrum-beta-lactamase (ESBL)-producing members of the Enterobacteriaceae are often resistant to multiple drug classes, making therapy of urinary infections with oral antibiotics difficult. Previously it was shown that amoxicillin-clavulanate can provide clavulanate inhibition of ESBLs and protect an oral cephalosporin present in combination when tested by broth microdilution. This study has shown that disk approximation testing could detect favorable cephalosporin-clavulanate interactions among a group of 101 previously characterized members of the Enterobacteriaceae with CTX-M, SHV, or TEM ESBLs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22170910      PMCID: PMC3295132          DOI: 10.1128/JCM.06248-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

Authors:  L A Miller; K Ratnam; D J Payne
Journal:  Curr Opin Pharmacol       Date:  2001-10       Impact factor: 5.547

Review 2.  Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.

Authors:  Johann D D Pitout; Patrice Nordmann; Kevin B Laupland; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

Review 3.  The pharmacokinetics of the oral cephalosporins--a review.

Authors:  R Wise
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

4.  Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.

Authors:  D Tremblay; A Dupront; C Ho; D Coussediere; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

5.  Practical methods using boronic acid compounds for identification of class C beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Authors:  Tetsuya Yagi; Jun-ichi Wachino; Hiroshi Kurokawa; Satowa Suzuki; Kunikazu Yamane; Yohei Doi; Naohiro Shibata; Haru Kato; Keigo Shibayama; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Pharmacokinetics of clavulanic acid, given in combination with amoxycillin, in volunteers.

Authors:  I Nilsson-Ehle; H Fellner; S A Hedström; P Nilsson-Ehle; J Sjövall
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

Review 7.  Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact.

Authors:  Jesús Oteo; María Pérez-Vázquez; José Campos
Journal:  Curr Opin Infect Dis       Date:  2010-08       Impact factor: 4.915

Review 8.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

9.  Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects.

Authors:  D J Weber; N E Tolkoff-Rubin; R H Rubin
Journal:  Pharmacotherapy       Date:  1984 May-Jun       Impact factor: 4.705

10.  Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses.

Authors:  M Richer; S Allard; L Manseau; F Vallée; R Pak; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  3 in total

1.  In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection.

Authors:  Edouard Bingen; Philippe Bidet; André Birgy; Elsa Sobral; Patricia Mariani; Robert Cohen
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.

Authors:  James Cohen Stuart; Maurine Leverstein-Van Hall; Willemijn Kortmann; J Verlind; Frouke Mulder; Jelle Scharringa; Ad Fluit; Miquel Ekkelenkamp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-16       Impact factor: 3.267

3.  Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.

Authors:  Gabriel Lignieres; André Birgy; Camille Jung; Stéphane Bonacorsi; Corinne Levy; François Angoulvant; Emmanuel Grimprel; Marie Aliette Dommergues; Yves Gillet; Irina Craiu; Alexis Rybak; Loic De Pontual; François Dubos; Emmanuel Cixous; Vincent Gajdos; Didier Pinquier; Isabelle Andriantahina; Valérie Soussan-Banini; Emilie Georget; Elise Launay; Olivier Vignaud; Robert Cohen; Fouad Madhi
Journal:  PLoS One       Date:  2021-09-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.